Ranolazine for Chronic Angina Management
Indications and Patient Selection
- The European Society of Cardiology recommends ranolazine as add-on therapy in patients with inadequate symptom control while on beta-blockers and/or calcium channel blockers (Class IIa, Level B recommendation) 1
- Ranolazine is particularly useful in patients with bradycardia or hypotension who cannot tolerate rate-lowering or blood pressure-lowering agents, diabetic patients with chronic stable angina, and patients with left ventricular hypertrophy 1, 2
Dosing Regimen
- The American Heart Association suggests an initial dose of 500 mg orally twice daily, with a maximum dose of 1000 mg orally twice daily, titrated based on clinical symptom response 3
Mechanism and Hemodynamic Profile
- Ranolazine inhibits the late sodium current (late INa), preventing intracellular calcium overload during ischemia without significantly affecting heart rate or blood pressure, as stated by the American College of Cardiology 1, 3
- This hemodynamically neutral profile distinguishes ranolazine from traditional antianginal agents, making it advantageous when rate or blood pressure reduction is undesirable 1, 3
Expected Clinical Benefits
- Ranolazine reduces angina frequency and nitroglycerin use, with the European Society of Cardiology noting its effectiveness in symptom relief 1
- Important limitation: Ranolazine provides symptom relief but does not reduce major cardiovascular events (cardiovascular death, myocardial infarction) or improve mortality, as reported by the American Heart Association 1, 3
Contraindications
- Absolute contraindications include liver cirrhosis or hepatic impairment, as stated by the European Association for the Study of the Liver 1